Want to see IT:SOL full AI Analyst Report?
SOL Stock Chart & Stats
€53.90
-€0.70(-1.11%)
At close: 4:00 PM EDT
€53.90
-€0.70(-1.11%)
Day’s Range― - ―
52-Week Range€44.85 - €64.00
Previous CloseN/A
Volume24.26K
Average Volume (3M)43.97K
Market Cap
€5.41B
Enterprise Value€5.88B
Total Cash (Recent Filing)€312.81M
Total Debt (Recent Filing)€878.27M
Price to Earnings (P/E)31.3
Beta0.28
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.75%
Share Statistics
EPS (TTM)1.91
Shares Outstanding90,700,000
10 Day Avg. Volume43,389
30 Day Avg. Volume43,972
Financial Highlights & Ratios
PEG Ratio2.06
Price to Book (P/B)3.91
Price to Sales (P/S)2.50
P/FCF Ratio178.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.12
Revenue Forecast (FY)€1.98B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthA multi-year record of positive revenue growth indicates sustained demand and expanding business activity rather than a single-period improvement. The 2025 re-acceleration is particularly constructive because it supports continued scale, investment capacity, and resilience over the next several quarters.
Stable Operating MarginsMaintaining mid-teens EBIT margins and consistently strong EBITDA margins demonstrates solid operating economics despite changing conditions. This profitability profile can support reinvestment, absorb moderate cost pressure, and provide a durable earnings base if revenue growth continues.
Positive Cash Flow And Healthy ReturnsPositive, fairly stable operating cash flow shows that the company converts its profitable operations into cash, while healthy returns on equity indicate productive use of shareholder capital. Together, these qualities support ongoing operations and reinforce the business's underlying financial performance.
Bears Say
Declining Free Cash FlowDeclining free cash flow weakens the quality of reported earnings and reduces internally generated funds available for investment, debt reduction, or shareholder returns. If the pressure persists, the company may have less flexibility to fund growth and absorb operating or capital-spending demands.
Higher 2025 LeverageThe increase in debt and debt-to-equity reduces balance-sheet flexibility compared with the prior year. Greater leverage can raise financing sensitivity and leave fewer resources available for strategic investment, particularly if earnings soften or higher interest rates persist over the medium term.
Gross Margin VolatilityLarge swings in gross margin introduce uncertainty into earnings quality because they may reflect changing input costs, pricing, or product mix. Even with stable EBIT margins, recurring volatility at this level can make profitability less predictable and complicate medium-term planning.
SOL SPA News
SOL FAQ
What was SOL SPA’s price range in the past 12 months?
SOL SPA lowest stock price was €44.85 and its highest was €64.00 in the past 12 months.
What is SOL SPA’s market cap?
SOL SPA’s market cap is €5.41B.
When is SOL SPA’s upcoming earnings report date?
SOL SPA’s upcoming earnings report date is Apr 01, 2027 which is in 154 days.
How were SOL SPA’s earnings last quarter?
SOL SPA released its earnings results on Sep 03, 2026. The company reported €0.991 earnings per share for the quarter.
Is SOL SPA overvalued?
According to Wall Street analysts SOL SPA’s price is currently Overvalued.
Does SOL SPA pay dividends?
SOL SPA pays a Annually dividend of €0.45 which represents an annual dividend yield of 0.75%. See more information on SOL SPA dividends here
What is SOL SPA’s EPS estimate?
SOL SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SOL SPA have?
SOL SPA has 90,700,000 shares outstanding.
What happened to SOL SPA’s price movement after its last earnings report?
SOL SPA reported an EPS of €0.991 in its last earnings report. Following the earnings report the stock price went up 1.241%.
Which hedge fund is a major shareholder of SOL SPA?
Currently, no hedge funds are holding shares in IT:SOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SOL SPA
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.